Oesophagus, Stomach Cancer Cancer Malignant neopplasm of other or ill-defined digestive organs
Conditions
Interventions
Patients are randomised to one of four treatment arms:
1. Arm A: Chemotherapy with FEMTX
2. Arm B: Chemotherapy with FEMTX plus Granulocyte Colony Stimulating Factor (G
Sponsors
Pharmacia Ltd & Upjohn (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged less than 70 years 2. Histologically confirmed locally advanced and/or metastatic gastric cancer 3. Measurable or evaluable disease 4. Karnofsky status 80-100 5. Adequate renal, hepatic and bone marrow function
Exclusion criteria
Exclusion criteria: 1. Previous chemotherapy or radiotherapy 2. Pleural or peritoneal effusions which cannot be adequately drained 3. Central Nervous System (CNS) metastases 4. History of previous or concomitant malignancy except squamous or basal cell carcinoma of the skin which has been effectively treated and carcinoma in situ of the cervix which has been treated operatively only 5. Other medical contraindications to treatment protocols
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed